

Stefano Faggiuoli

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1584815/publications.pdf>

Version: 2024-02-01

181
papers

9,000
citations

50566

48
h-index

53065

89
g-index

190
all docs

190
docs citations

190
times ranked

11469
citing authors

#	ARTICLE	IF	CITATIONS
1	Liver transplantation in patients with non-neoplastic portal vein thrombosis: 20 years of experience in a single center. <i>Clinical Transplantation</i> , 2022, 36, e14501.	0.8	4
2	Dysmetabolism, Diabetes and Clinical Outcomes in Patients Cured of Chronic Hepatitis C: A Real-Life Cohort Study. <i>Hepatology Communications</i> , 2022, 6, 867-877.	2.0	6
3	Effects of immunosuppressive drugs on COVID-19 severity in patients with autoimmune hepatitis. <i>Liver International</i> , 2022, 42, 607-614.	1.9	26
4	Dexrazoxane for rapid extended livedo reticularis-like skin reaction due to systemic epirubicin diffusion during transcatheter arterial chemoembolization procedure for hepatocellular carcinoma. <i>Journal of Cancer Research and Therapeutics</i> , 2022, 18, 501.	0.3	2
5	Meet-Test-Treat for HCV management: patients' and clinicians' preferences in hospital and drug addiction services in Italy. <i>BMC Infectious Diseases</i> , 2022, 22, 3.	1.3	4
6	R3-AFP score is a new composite tool to refine prediction of hepatocellular carcinoma recurrence after liver transplantation. <i>JHEP Reports</i> , 2022, 4, 100445.	2.6	6
7	Frequency, characteristics, and outcome of patients with COVID-19 pneumonia and "silent hypoxemia" at admission: a severity-matched analysis. <i>Panminerva Medica</i> , 2022, 64, .	0.2	4
8	Implementation of HCV screening in the 1969-1989 birth cohort undergoing COVID-19 vaccination. <i>Liver International</i> , 2022, 42, 1012-1016.	1.9	13
9	Antecedent use of renin-angiotensin system inhibitors is associated with reduced mortality in elderly hypertensive Covid-19 patients. <i>Journal of Hypertension</i> , 2022, 40, 666-674.	0.3	4
10	A Very Short Course of HBIg+NA Followed by Entecavir or Tenofovir Monotherapy Prevents HBV Recurrence in Low-Risk Liver Transplant Recipients. <i>Transplantation Proceedings</i> , 2021, 53, 207-214.	0.3	3
11	High rates of sustained virological response despite premature discontinuation of directly acting antivirals in HCV-infected patients treated in a real-life setting. <i>Journal of Viral Hepatitis</i> , 2021, 28, 558-568.	1.0	3
12	Impact of immunosuppressive therapy on the severity of COVID-19 in solid organ transplant recipients. <i>Journal of Infection</i> , 2021, 82, 414-451.	1.7	8
13	On-treatment serum albumin level can guide long-term treatment in patients with cirrhosis and uncomplicated ascites. <i>Journal of Hepatology</i> , 2021, 74, 340-349.	1.8	38
14	Predicting in-hospital mortality from Coronavirus Disease 2019: A simple validated app for clinical use. <i>PLoS ONE</i> , 2021, 16, e0245281.	1.1	25
15	Third-party bone marrow-derived mesenchymal stromal cell infusion before liver transplantation: A randomized controlled trial. <i>American Journal of Transplantation</i> , 2021, 21, 2795-2809.	2.6	20
16	At the peak of COVID-19 age and disease severity but not comorbidities are predictors of mortality: COVID-19 burden in Bergamo, Italy. <i>Panminerva Medica</i> , 2021, 63, 51-61.	0.2	33
17	Bergamo and Covid-19: How the Dark Can Turn to Light. <i>Frontiers in Medicine</i> , 2021, 8, 609440.	1.2	15
18	Pregnancy after liver transplantation: a survey from Italian liver transplants centres. <i>Digestive and Liver Disease</i> , 2021, 53, S12-S13.	0.4	0

#	ARTICLE	IF	CITATIONS
19	Covid-19 and gender: lower rate but same mortality of severe disease in women – an observational study. <i>BMC Pulmonary Medicine</i> , 2021, 21, 96.	0.8	40
20	Real-world experience with obeticholic acid in patients with primary biliary cholangitis. <i>JHEP Reports</i> , 2021, 3, 100248.	2.6	33
21	Siltuximab downregulates interleukin-8 and pentraxin 3 to improve ventilatory status and survival in severe COVID-19. <i>Leukemia</i> , 2021, 35, 2710-2714.	3.3	42
22	X Chromosome Contribution to the Genetic Architecture of Primary Biliary Cholangitis. <i>Gastroenterology</i> , 2021, 160, 2483-2495.e26.	0.6	27
23	International study on the outcome of locoregional therapy for liver transplant in hepatocellular carcinoma beyond Milan criteria. <i>JHEP Reports</i> , 2021, 3, 100331.	2.6	10
24	Endothelium Activation Markers in Severe Hospitalized COVID-19 Patients: Role in Mortality Risk Prediction. <i>TH Open</i> , 2021, 05, e253-e263.	0.7	16
25	COVID-19 in liver transplant candidates: pretransplant and post-transplant outcomes - an ELITA/ELTR multicentre cohort study. <i>Gut</i> , 2021, 70, 1914-1924.	6.1	30
26	Drug – Drug Interactions in Italian Patients with Chronic Hepatitis C Treated with Pangenotypic Direct Acting Agents: Insights from a Real-World Study. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 7144.	1.2	10
27	An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs. <i>Journal of Hepatology</i> , 2021, 75, 572-581.	1.8	62
28	Liver transplantation for patients with acute-on-chronic liver failure (ACLF) in Europe: Results of the ELITA/EF-CLIF collaborative study (ECLIS). <i>Journal of Hepatology</i> , 2021, 75, 610-622.	1.8	96
29	Association between inhibitors of the renin – angiotensin system and lung function in elderly patients recovered from severe COVID-19. <i>European Journal of Preventive Cardiology</i> , 2021, , .	0.8	3
30	Pre-Transplant Alpha-Fetoprotein > 25.5 and Its Dynamic on Waitlist Are Predictors of HCC Recurrence after Liver Transplantation for Patients Meeting Milan Criteria. <i>Cancers</i> , 2021, 13, 5976.	1.7	4
31	Role of transaminases, CRP and LDH in COVID-19 patients with and without respiratory failure during the disease outbreak. <i>Medical Research Archives</i> , 2021, 9, .	0.1	0
32	Preparing for future waves and pandemics: a global hospital survey on infection control measures and infection rates in COVID-19. <i>Antimicrobial Resistance and Infection Control</i> , 2021, 10, 170.	1.5	2
33	Clinical outcome indicators in chronic hepatitis B and C: A primer for value – based medicine in hepatology. <i>Liver International</i> , 2020, 40, 60-73.	1.9	5
34	Outcomes of Liver Transplant for Adults With Wilson – s Disease. <i>Liver Transplantation</i> , 2020, 26, 507-516.	1.3	12
35	Renal safety in 3264 HCV patients treated with DAA-based regimens: Results from a large Italian real-life study. <i>Digestive and Liver Disease</i> , 2020, 52, 190-198.	0.4	12
36	Coronavirus Disease 2019 in Autoimmune Hepatitis: A Lesson From Immunosuppressed Patients. <i>Hepatology Communications</i> , 2020, 4, 1257-1262.	2.0	55

#	ARTICLE	IF	CITATIONS
37	Endothelial injury and thrombotic microangiopathy in COVID-19: Treatment with the lectin-pathway inhibitor narsoplimab. <i>Immunobiology</i> , 2020, 225, 152001.	0.8	120
38	Severity of respiratory failure and outcome of patients needing a ventilatory support in the Emergency Department during Italian novel coronavirus SARS-CoV2 outbreak: Preliminary data on the role of Helmet CPAP and Non-Invasive Positive Pressure Ventilation. <i>EClinicalMedicine</i> , 2020, 24, 100419.	3.2	67
39	Immunosuppressive regimens for adult liver transplant recipients in real-life practice: consensus recommendations from an Italian Working Group. <i>Hepatology International</i> , 2020, 14, 930-943.	1.9	37
40	Health related quality of life in chronic liver diseases. <i>Liver International</i> , 2020, 40, 2630-2642.	1.9	15
41	International, multicenter study on the outcome of locoregional therapy before liver transplant for hepatocellular carcinoma extending the Milan criteria. <i>Journal of Hepatology</i> , 2020, 73, S8.	1.8	0
42	Reassessment of the risk of recurrence (R3) after liver transplantation for HCC: validation of the R3 v.2 score and comparison with existing models: results of a multinational analysis in 2,444 patients. <i>Journal of Hepatology</i> , 2020, 73, S9-S11.	1.8	0
43	Recent trends and intention-to-treat survival of liver transplantation for non-alcoholic steatohepatitis: an Italian liver transplant registry study. On behalf of AISF, FIRE, SITO and CNT. <i>Journal of Hepatology</i> , 2020, 73, S252.	1.8	0
44	Impact of dysmetabolism on liver damage severity and evolution in a real-life cohort of patients treated for chronic hepatitis C. <i>Journal of Hepatology</i> , 2020, 73, S327.	1.8	0
45	Long-term albumin administration is not futile in patients with cirrhosis and uncomplicated ascites not normalizing serum albumin concentration with treatment. <i>Journal of Hepatology</i> , 2020, 73, S738.	1.8	0
46	Adaptations and Lessons in the Province of Bergamo. <i>New England Journal of Medicine</i> , 2020, 382, e71.	13.9	111
47	Health status of patients with autoimmune liver disease during SARS-CoV-2 outbreak in northern Italy. <i>Journal of Hepatology</i> , 2020, 73, 702-705.	1.8	48
48	High rates of 30-day mortality in patients with cirrhosis and COVID-19. <i>Journal of Hepatology</i> , 2020, 73, 1063-1071.	1.8	279
49	Papa Giovanni XXIII Bergamo Hospital at the time of the COVID-19 outbreak: Letter from the warfront. <i>International Journal of Laboratory Hematology</i> , 2020, 42, 8-10.	0.7	42
50	Liver transplantation in hepatocellular carcinoma after tumour downstaging (XXL): a randomised, controlled, phase 2b/3 trial. <i>Lancet Oncology</i> , The, 2020, 21, 947-956.	5.1	166
51	Comparison of three therapeutic regimens for genotype 3 hepatitis C virus infection in a large real-life multicentre cohort. <i>Liver International</i> , 2020, 40, 769-777.	1.9	15
52	Global real-world evidence of sofosbuvir/velpatasvir as simple, effective HCV treatment: Analysis of 5552 patients from 12 cohorts. <i>Liver International</i> , 2020, 40, 1841-1852.	1.9	66
53	Extensive Characterization of the Hemostatic Derangement Occurring in COVID-19 Patients Admitted to the Bergamo Hospital. <i>Blood</i> , 2020, 136, 36-36.	0.6	1
54	Real-life effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients with previous DAA failure. <i>Journal of Hepatology</i> , 2019, 71, 1106-1115.	1.8	69

#	ARTICLE	IF	CITATIONS
55	THU-166-Treatment of 320 genotype 3 cirrhotic patients with 12 weeks of sofosbuvir/velpatasvir with or without ribavirin: Real life experience from Italy. <i>Journal of Hepatology</i> , 2019, 70, e234-e235.	1.8	1
56	The Liver in Systemic Illness. , 2019, , 361-396.		1
57	HepaDisk â€œ A new quality of life questionnaire for HCV patients. <i>Digestive and Liver Disease</i> , 2019, 51, 1008-1015.	0.4	3
58	Daclatasvir-based regimens in HCV cirrhosis: experience from the Italian early access program. <i>Scientific Reports</i> , 2019, 9, 585.	1.6	6
59	Changes in hepatitis C burden and treatment trends in Europe during the era of direct-acting antivirals: a modelling study. <i>BMJ Open</i> , 2019, 9, e026726.	0.8	34
60	GS-03-Global real world evidence of sofosbuvir/velpatasvir as a simple, effective regimen for the treatment of chronic hepatitis C patients: Integrated analysis of 12 clinical practice cohorts. <i>Journal of Hepatology</i> , 2019, 70, e2-e3.	1.8	11
61	Current and forthcoming perspectives in linkage to care of hepatitis C virus infection: Assessment of an Italian focus group. <i>Digestive and Liver Disease</i> , 2019, 51, 915-921.	0.4	13
62	Prophylaxis of spontaneous bacterial peritonitis: Is there still room for quinolones?. <i>Journal of Hepatology</i> , 2019, 70, 1027-1028.	1.8	5
63	Long-term albumin administration in patients with cirrhosis and uncomplicated ascites: the use of serum albumin concentration for personalizing treatment. <i>Digestive and Liver Disease</i> , 2019, 51, e9.	0.4	2
64	Management of adverse events associated with idelalisib treatment in chronic lymphocytic leukemia and follicular lymphoma: A multidisciplinary position paper. <i>Hematological Oncology</i> , 2019, 37, 3-14.	0.8	59
65	Real life experiences in HCV management in 2018. <i>Expert Review of Anti-Infective Therapy</i> , 2019, 17, 117-128.	2.0	8
66	Real-world effectiveness and safety of glecaprevir/pibrentasvir in 723 patients with chronic hepatitis C. <i>Journal of Hepatology</i> , 2019, 70, 379-387.	1.8	109
67	AISF position paper on HCV in immunocompromised patients. <i>Digestive and Liver Disease</i> , 2019, 51, 10-23.	0.4	5
68	Effectiveness and safety of switching to entecavir hepatitis B patients developing kidney dysfunction during tenofovir. <i>Liver International</i> , 2019, 39, 484-493.	1.9	9
69	Economic Evaluation of Different Organizational Models for the Management of Patients with Hepatitis C. <i>Farmeconomia E Percorsi Terapeutici</i> , 2019, 20, .	0.2	1
70	Treatment of hepatocellular carcinoma: a cost analysis of yttrium-90 transarterial radioembolization versus sorafenib. <i>Future Oncology</i> , 2018, 14, 727-735.	1.1	5
71	Value of HCC-MELD Score in Patients With Hepatocellular Carcinoma Undergoing Liver Transplantation. <i>Progress in Transplantation</i> , 2018, 28, 63-69.	0.4	12
72	Under-dilated TIPS Associate With Efficacy and Reduced Encephalopathy in a Prospective, Non-randomized Study of Patients With Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 1153-1162.e7.	2.4	90

#	ARTICLE	IF	CITATIONS
73	Optimising the clinical strategy for autoimmune liver diseases: Principles of value-based medicine. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2018, 1864, 1415-1422.	1.8	3
74	The Italian compassionate use of sofosbuvir in <scp>HCV</scp> patients waitlisted for liver transplantation: A national real-life experience. <i>Liver International</i> , 2018, 38, 733-741.	1.9	5
75	Sofosbuvir plus daclatasvir with or without ribavirin is safe and effective for post-transplant hepatitis C recurrence and severe fibrosis and cirrhosis: A prospective study. <i>Clinical Transplantation</i> , 2018, 32, e13165.	0.8	10
76	Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial. <i>Lancet, The</i> , 2018, 391, 2417-2429.	6.3	345
77	Î±1-Antitrypsin Polymerizes in Alveolar Macrophages of Smokers With and Without Î±1-Antitrypsin Deficiency. <i>Chest</i> , 2018, 154, 607-616.	0.4	22
78	Delisting <scp>HCV</scp>-infected liver transplant candidates who improved after viral eradication: Outcome 2 years after delisting. <i>Liver International</i> , 2018, 38, 2170-2177.	1.9	54
79	Antibiotic stewardship and empirical antibiotic treatment: How can they get along?. <i>Digestive and Liver Disease</i> , 2017, 49, 579-584.	0.4	10
80	Long-term outcomes of direct acting antivirals in post-transplant advanced hepatitis C virus recurrence and fibrosing cholestatic hepatitis. <i>Journal of Viral Hepatitis</i> , 2017, 24, 858-864.	1.0	11
81	Treatment of Hepatitis C virus infection in Italy: A consensus report from an expert panel. <i>Digestive and Liver Disease</i> , 2017, 49, 731-741.	0.4	19
82	International Liver Transplantation Society Consensus Statement on Hepatitis C Management in Liver Transplant Candidates. <i>Transplantation</i> , 2017, 101, 945-955.	0.5	76
83	International Liver Transplantation Society Consensus Statement on Hepatitis C Management in Liver Transplant Recipients. <i>Transplantation</i> , 2017, 101, 956-967.	0.5	44
84	Validation of the AFP model as a predictor of HCC recurrence in patients with viral hepatitis-related cirrhosis who had received a liver transplant for HCC. <i>Journal of Hepatology</i> , 2017, 66, 552-559.	1.8	166
85	Efficacy, safety, and pharmacokinetics of simeprevir, daclatasvir, and ribavirin in patients with recurrent hepatitis C virus genotype 1b infection after orthotopic liver transplantation: The Phase <scp>II SATURN</scp> study. <i>Transplant Infectious Disease</i> , 2017, 19, e12696.	0.7	10
86	ELITA consensus statements on the use of DAAs in liver transplant candidates and recipients. <i>Journal of Hepatology</i> , 2017, 67, 585-602.	1.8	71
87	Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 427-434.	3.7	15
88	The Italian compassionate use of sofosbuvir observational cohort study for the treatment of recurrent hepatitis C: clinical and virological outcomes. <i>Transplant International</i> , 2017, 30, 1253-1265.	0.8	3
89	Use of Everolimus in Liver Transplantation. <i>Transplantation</i> , 2017, 101, 239-251.	0.5	54
90	Consensus conference on TIPS management: Techniques, indications, contraindications. <i>Digestive and Liver Disease</i> , 2017, 49, 121-137.	0.4	111

#	ARTICLE	IF	CITATIONS
91	Successful Pre- and Posttransplant Sofosbuvir-Based Anti-Hepatitis C Virus Treatment in Persons Living With Human Immunodeficiency Virus Infection. <i>Open Forum Infectious Diseases</i> , 2017, 4, ofx065.	0.4	9
92	Prevalent use of combined prophylaxis of hepatitis B after liver transplantation in Italy: results of a national survey in a large cohort. <i>Minerva Gastroenterology</i> , 2017, 64, 1-9.	0.3	3
93	Gut microbiota in autism and mood disorders. <i>World Journal of Gastroenterology</i> , 2016, 22, 361.	1.4	300
94	Managing hepatitis C virusâ€”HIV liver transplant recipients with the new direct-acting antivirals. <i>Aids</i> , 2016, 30, 323-325.	1.0	0
95	Obliterative portal venopathy without portal hypertension: an underestimated condition. <i>Liver International</i> , 2016, 36, 454-460.	1.9	57
96	Delisting of liver transplant candidates with chronic hepatitis C after viral eradication: A European study. <i>Journal of Hepatology</i> , 2016, 65, 524-531.	1.8	298
97	From current status to optimization of HCV treatment: Recommendations from an expert panel. <i>Digestive and Liver Disease</i> , 2016, 48, 995-1005.	0.4	13
98	Predictive value of nodule size and differentiation in HCC recurrence after liver transplantation. <i>Surgical Oncology</i> , 2016, 25, 419-428.	0.8	33
99	Emerging biological agents for hepatitis C. <i>Expert Opinion on Emerging Drugs</i> , 2016, 21, 219-224.	1.0	2
100	Hepatitis C virus and liver transplantation: where do we stand?. <i>Transplant International</i> , 2016, 29, 135-152.	0.8	12
101	The societal burden of chronic liver diseases: results from the COME study. <i>BMJ Open Gastroenterology</i> , 2015, 2, e000025.	1.1	38
102	Cost-effectiveness of pretransplant sofosbuvir for preventing recurrent hepatitis C virus infection after liver transplantation. <i>Transplant International</i> , 2015, 28, 1055-1065.	0.8	7
103	A Multistep, Consensus-Based Approach to Organ Allocation in Liver Transplantation: Toward a â€œBlended Principle Modelâ€. <i>American Journal of Transplantation</i> , 2015, 15, 2552-2561.	2.6	164
104	Management of hepatitis C infection before and after liver transplantation. <i>World Journal of Gastroenterology</i> , 2015, 21, 4447-4456.	1.4	18
105	Open versus laparoscopic cholecystectomy in acute cholecystitis. Systematic review and meta-analysis. <i>International Journal of Surgery</i> , 2015, 18, 196-204.	1.1	252
106	Refining sorafenib therapy: lessons from clinical practice. <i>Future Oncology</i> , 2015, 11, 449-465.	1.1	17
107	MicroRNAâ€”425â€”3p predicts response to sorafenib therapy in patients with hepatocellular carcinoma. <i>Liver International</i> , 2015, 35, 1077-1086.	1.9	68
108	Management of infections in cirrhotic patients: Report of a Consensus Conference. <i>Digestive and Liver Disease</i> , 2014, 46, 204-212.	0.4	40

#	ARTICLE	IF	CITATIONS
109	Management of infections pre- and post-liver transplantation: Report of an AISF consensus conference. <i>Journal of Hepatology</i> , 2014, 60, 1075-1089.	1.8	77
110	Long-term maintenance of sustained virological response in liver transplant recipients treated for recurrent hepatitis C. <i>Digestive and Liver Disease</i> , 2014, 46, 440-445.	0.4	3
111	A method for establishing allocation equity among patients with and without hepatocellular carcinoma on a common liver transplant waiting list. <i>Journal of Hepatology</i> , 2014, 60, 290-297.	1.8	89
112	White Paper of Italian Gastroenterology: Delivery of services for digestive diseases in Italy: Weaknesses and strengths. <i>Digestive and Liver Disease</i> , 2014, 46, 579-589.	0.4	40
113	Use of Anti-HCV Positive Grafts in Liver Transplantation. , 2014, , 107-116.		0
114	Comparing the performance of the standard EQ-5D 3L with the new version EQ-5D 5L in patients with chronic hepatic diseases. <i>Quality of Life Research</i> , 2013, 22, 1707-1716.	1.5	108
115	Skills and Requirements of a Transplant Hepatologist: Board Certification of the Italian Association for the Study of the Liver (AISF). <i>Digestive and Liver Disease</i> , 2013, 45, 992-994.	0.4	3
116	Monogenic diseases that can be cured by liver transplantation. <i>Journal of Hepatology</i> , 2013, 59, 595-612.	1.8	111
117	Interaction between calcineurin inhibitors and IL-28B rs12979860 C>T polymorphism and response to treatment for post-transplant recurrent hepatitis C. <i>Digestive and Liver Disease</i> , 2013, 45, 927-932.	0.4	5
118	Hepatitis B in immunosuppressed cancer patients: Pathogenesis, incidence and prophylaxis. <i>Critical Reviews in Oncology/Hematology</i> , 2013, 87, 12-27.	2.0	19
119	Treatment of genotype-1 hepatitis C recurrence after liver transplant improves survival in both sustained responders and relapsers. <i>Transplant International</i> , 2013, 26, 281-289.	0.8	7
120	Hepatitis B-core antibody positive donors in liver transplantation and their impact on graft survival: Evidence from the Liver Match cohort study. <i>Journal of Hepatology</i> , 2013, 58, 715-723.	1.8	44
121	A Phase II Randomized Dose Escalation Trial of Sorafenib in Patients With Advanced Hepatocellular Carcinoma. <i>Oncologist</i> , 2013, 18, 379-380.	1.9	34
122	Results of a Stepwise Approach to Extrahepatic Portal Vein Obstruction in Children. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2013, 57, 619-626.	0.9	29
123	Small Hepatocellular Carcinomas and Thrombocytopenia. <i>Oncology</i> , 2012, 83, 331-338.	0.9	22
124	Analytical evaluation of Sysmex UF-1000i for flow cytometric analysis of peritoneal fluid. <i>Clinical Biochemistry</i> , 2012, 45, 1263-1265.	0.8	25
125	Antiviral therapy and fibrosis progression in patients with mild to moderate hepatitis C recurrence after liver transplantation. A randomized controlled study. <i>Digestive and Liver Disease</i> , 2012, 44, 603-609.	0.4	12
126	http://www.D-MELD.com , the Italian survival calculator to optimize donor to recipient matching and to identify the unsustainable matches in liver transplantation. <i>Transplant International</i> , 2012, 25, 294-301.	0.8	26

#	ARTICLE	IF	CITATIONS
127	Treatment of hepatitis C recurrence is less successful in female than in male liver transplant recipients. <i>Transplant International</i> , 2012, 25, 448-454.	0.8	11
128	Will direct-acting antivirals make a difference in HIV/HCV coinfecting patients?. <i>Expert Review of Anti-Infective Therapy</i> , 2011, 9, 699-701.	2.0	0
129	Liver Match, a prospective observational cohort study on liver transplantation in Italy: Study design and current practice of donor/recipient matching. <i>Digestive and Liver Disease</i> , 2011, 43, 155-164.	0.4	69
130	Diagnosis, treatment and survival of patients with hepatorenal syndrome: A survey on daily medical practice. <i>Journal of Hepatology</i> , 2011, 55, 1241-1248.	1.8	87
131	Facing HCV recurrence after liver transplantation: antiviral therapy response and clinical outcome. <i>Digestive and Liver Disease Supplements</i> , 2011, 5, 30-35.	0.2	0
132	What can we learn about biofilm/host interactions from the study of inflammatory bowel disease. <i>Journal of Clinical Periodontology</i> , 2011, 38, 36-43.	2.3	33
133	Balancing Donor and Recipient Risk Factors in Liver Transplantation: The Value of D-MELD With Particular Reference to HCV Recipients. <i>American Journal of Transplantation</i> , 2011, 11, 2724-2736.	2.6	86
134	Management of Hepatitis C Virus Infection Recurrence After Liver Transplantation: An Overview. <i>Transplantation Proceedings</i> , 2011, 43, 291-295.	0.3	21
135	Small HCCs Identified by Screening. <i>Digestive Diseases and Sciences</i> , 2011, 56, 3078-3085.	1.1	8
136	Prediction of progression-free survival in patients presenting with hepatocellular carcinoma within the Milan criteria. <i>Liver Transplantation</i> , 2010, 16, 503-512.	1.3	41
137	Donor livers with steatosis are safe to use in hepatitis C virus-positive recipients. <i>Liver Transplantation</i> , 2009, 15, 619-628.	1.3	41
138	Serum Ferritin as a Predictor of Treatment Outcome in Patients With Chronic Hepatitis C. <i>American Journal of Gastroenterology</i> , 2009, 104, 605-616.	0.2	35
139	Endogenous Interferon- λ Level is Increased in Hepatitis C Virus (HCV)-Positive Pregnant Women. <i>Journal of Clinical Gastroenterology</i> , 2008, 42, 204-207.	1.1	9
140	Hepatitis C Infection in Patients with Chronic Kidney Disease. <i>International Journal of Artificial Organs</i> , 2008, 31, 15-33.	0.7	13
141	Different neurological outcome of liver transplantation for Wilson's disease in two homozygotic twins. <i>Clinical Neurology and Neurosurgery</i> , 2007, 109, 71-75.	0.6	41
142	Prophylaxis and treatment of hepatitis B in immunocompromised patients. <i>Digestive and Liver Disease</i> , 2007, 39, 397-408.	0.4	197
143	Renal failure and bacterial infections in patients with cirrhosis: Epidemiology and clinical features. <i>Hepatology</i> , 2007, 45, 223-229.	3.6	282
144	Sustained virological response to interferon- λ is associated with improved outcome in HCV-related cirrhosis: A retrospective study. <i>Hepatology</i> , 2007, 45, 579-587.	3.6	585

#	ARTICLE	IF	CITATIONS
145	Liver transplantation for HCV cirrhosis: Improved survival in recent years and increased severity of recurrent disease in female recipients: Results of a long term retrospective study. <i>Liver Transplantation</i> , 2007, 13, 733-740.	1.3	124
146	HLA-DRB1 Donor-Recipient Mismatch Affects the Outcome of Hepatitis C Disease Recurrence After Liver Transplantation. <i>Gastroenterology</i> , 2006, 130, 695-702.	0.6	29
147	Hepatitis C minimal residual viremia (MRV) detected by TMA at the end of Peg-IFN plus ribavirin therapy predicts post-treatment relapse. <i>Journal of Hepatology</i> , 2006, 44, 83-87.	1.8	48
148	Antiviral Therapy for Hepatitis C Virus Recurrence Following Liver Transplantation: Long-Term Results From a Single Center Experience. <i>Transplantation Proceedings</i> , 2006, 38, 1127-1130.	0.3	20
149	Diagnosis and Management of Wilson's Disease. <i>Journal of Clinical Gastroenterology</i> , 2006, 40, 936-941.	1.1	126
150	Fatal hepatic decompensation in a bone marrow transplant recipient with HBV-related cirrhosis following lamivudine withdrawal. <i>Gastroenterologie Clinique Et Biologique</i> , 2006, 30, 307-309.	0.9	4
151	Protocol liver biopsies in long-term management of patients transplanted for hepatitis B-related liver disease. <i>World Journal of Gastroenterology</i> , 2006, 12, 1706.	1.4	19
152	Percutaneous ablation procedures in cirrhotic patients with hepatocellular carcinoma submitted to liver transplantation: Assessment of efficacy at explant analysis and of safety for tumor recurrence. <i>Liver Transplantation</i> , 2005, 11, 1117-1126.	1.3	204
153	Liver transplantation for Wilson's disease: The burden of neurological and psychiatric disorders. <i>Liver Transplantation</i> , 2005, 11, 1056-1063.	1.3	149
154	Neuropsychological and Neurophysiological Evaluation in Cirrhotic Patients With Minimal Hepatic Encephalopathy Undergoing Liver Transplantation. <i>Transplantation Proceedings</i> , 2005, 37, 1104-1107.	0.3	24
155	Comparison Between Nifedipine and Carvedilol in the Treatment of de novo Arterial Hypertension After Liver Transplantation: Preliminary Results of a Controlled Clinical Trial. <i>Transplantation Proceedings</i> , 2005, 37, 1245-1247.	0.3	9
156	Anemia and ischemia: Myocardial injury in patients with gastrointestinal bleeding. <i>American Journal of Medicine</i> , 2005, 118, 548-551.	0.6	37
157	The critical issue of hepatocellular carcinoma prognostic classification: which is the best tool available?. <i>Journal of Hepatology</i> , 2004, 40, 124-131.	1.8	161
158	Liver Transplantation for the Treatment of Moderately or Well-Differentiated Hepatocellular Carcinoma. <i>Annals of Surgery</i> , 2004, 239, 150-159.	2.1	289
159	Natural leukocyte interferon alfa for the treatment of chronic viral hepatitis in heart transplant recipients. <i>Transplantation</i> , 2003, 75, 982-986.	0.5	16
160	Histology predicts cirrhotic evolution of post transplant hepatitis C. <i>Gut</i> , 2002, 50, 697-700.	6.1	65
161	Histological features after liver transplantation in alcoholic cirrhotics. <i>Journal of Hepatology</i> , 2001, 34, 716-722.	1.8	90
162	HBV and HCV infections in heart transplant recipients. <i>Journal of Heart and Lung Transplantation</i> , 2001, 20, 718-724.	0.3	45

#	ARTICLE	IF	CITATIONS
163	Myocardial perfusion scintigraphy in patients with liver cirrhosis evaluated for orthotopic liver transplantation. <i>Transplantation Proceedings</i> , 2001, 33, 1447-1448.	0.3	7
164	Natural $\hat{\pm}$ -IFN in HCV recurrence after liver transplantation. <i>Transplantation Proceedings</i> , 2001, 33, 1457-1458.	0.3	8
165	Histological features of donor grafts for orthotopic liver transplantation. <i>Transplantation Proceedings</i> , 2001, 33, 1177-1178.	0.3	1
166	Bone Metabolism and Gonad Function in Male Patients Undergoing Liver Transplantation: A Two-Year Longitudinal Study. <i>Osteoporosis International</i> , 2001, 12, 749-754.	1.3	64
167	Fulminant hepatic failure: the issue of patient selection for hazardous liver assistance. <i>Transplantation Proceedings</i> , 2000, 32, 2719-2722.	0.3	1
168	Bone metabolism in orthotopic liver transplantation: A prospective study. <i>Liver Transplantation</i> , 1998, 4, 311-319.	1.9	49
169	Association between reactive oxygen species and disease activity in chronic hepatitis C. <i>Free Radical Biology and Medicine</i> , 1996, 21, 291-295.	1.3	206
170	Liver transplantation in virus-induced chronic liver disease. <i>Bailliere's Clinical Gastroenterology</i> , 1996, 10, 375-388.	0.9	3
171	Cryoglobulinemia: a cause for false negative polymerase chain reaction results in patients with hepatitis C virus positive chronic liver disease. <i>Journal of Hepatology</i> , 1995, 22, 464-467.	1.8	37
172	Gastrointestinal transit in cirrhotic patients: Effect of hepatic encephalopathy and its treatment. <i>Hepatology</i> , 1994, 19, 67-71.	3.6	55
173	Liver transplantation for hepatitis B virus-associated cirrhosis: A progress report. <i>Hepatology</i> , 1994, 20, S20-S23.	3.6	18
174	Response to interferon $\hat{\pm}$ therapy is influenced by the iron content of the liver. <i>Journal of Hepatology</i> , 1994, 20, 410-415.	1.8	222
175	The use of granulocyte-macrophage colony-stimulating factor to enhance hematologic parameters of patients with cirrhosis and hypersplenism. <i>Journal of Hepatology</i> , 1994, 21, 582-586.	1.8	14
176	Alpha-interferon treatment of hepatitis C in patients with liver allografts treated with either FK-506 or cyclosporin A. <i>European Journal of Gastroenterology and Hepatology</i> , 1994, 6, 787-792.	0.8	4
177	Preoperative evaluation of a patient for hepatic surgery. <i>Journal of Surgical Oncology</i> , 1993, 53, 49-51.	0.8	18
178	Biliary complications of liver transplantation. <i>Gastrointestinal Endoscopy</i> , 1993, 39, 455-460.	0.5	30
179	COVID-19 in Liver Transplant Candidates: Pre- and Post-Transplant Outcome. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
180	Clinical and Economic Benefits of a New Paradigm of HCV Diagnosis and Treatment. <i>Global & Regional Health Technology Assessment</i> , 0, 8, 58-66.	0.2	0

#	ARTICLE	IF	CITATIONS
181	Severity of Respiratory Failure and Outcome of Patients Needing a Ventilatory Support in the Emergency Department During Italian Novel Coronavirus SARS-CoV-2 Outbreak: Preliminary Data on the Role of Helmet CPAP and Non-Invasive Ventilation. SSRN Electronic Journal, 0, , .	0.4	3